Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134901 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Memantine in Treating Cocaine-Dependent Individuals - 2
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00134901 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 81 participants.
The verdict
NCT00134901, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
Cocaine is one of the most widely abused drugs in the United States. Memantine is a type of drug called an NMDA receptor antagonist. It works by decreasing normal excitement in the brain. NMDA receptor antagonists have shown to reduce cocaine-induced dopamine release in animal models, as well as lessen conditioned cocaine cues. The purpose of this study is to determine the effectiveness of memantine in preventing relapse to cocaine use in cocaine dependent individuals. In addition, this study will determine whether memantine produces better results than a placebo in decreasing cocaine craving, psychological symptoms, functional impairment, and discontinuation of treatment in cocaine dependent individuals.
Interventions
- DRUG placebo
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2003-03 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134901
The ClinicalTrials.gov registry entry for NCT00134901 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00134901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00134901 about?
NCT00134901 is a clinical study titled "Effectiveness of Memantine in Treating Cocaine-Dependent Individuals - 2". Cocaine is one of the most widely abused drugs in the United States. Memantine is a type of drug called an NMDA receptor antagonist. It works by decreasing normal excitement in the brain. NMDA receptor antagonists have shown to reduce cocaine-induced dopamine release in animal models, as well as les...
What is the current status of trial NCT00134901?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2003-03. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00134901?
The interventions under investigation include: placebo (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT00134901?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.